摘要
恶性黑色素脑转移发生率高,治疗效果不佳,是患者死亡的重要原因。近年来,随着众多小分子靶向药物(包括BRAF抑制剂、MEK抑制剂)和免疫治疗药物(如抗CTLA-4抗体、抗PD-1/PD-L1抗体)的问世,恶性黑色素脑转移的疗效得到提升。因此,本文从放疗、化疗、小分子靶向药物治疗、免疫治疗及联合治疗等5个方面系统性阐述恶性黑色素瘤脑转移治疗的最新进展,以期为临床工作提供新思路。
The poor prognosis of advanced malignant melanoma is strongly associated with its highly brain metastasis rates and poor therapeutic effects.Recently,new small molecular targeted drugs(BRAF inhibitors and MEK inhibitor)as well as immunotherapy(anti-CTLA-4 antibodies,anti-PD-1/PD-L1 antibodies),started to treat advanced malignant melanoma.These new drugs bring new hopes to improve the prognosis of melanoma brain metastases.In this paper,we reviewed the latest development of melanoma brain metastasis treatment in radiotherapy,chemotherapy,small molecule targeted drug therapy,immunotherapy and combination therapy in order to find out a better assessment for melanoma brain metastases.
作者
董永
孙季萍
楼芳
DONG Yong;SUN Jiping;LOU Fang(Department of Medical Oncology,Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University,Hangzhou 310016,China)
出处
《临床肿瘤学杂志》
CAS
北大核心
2019年第10期948-953,共6页
Chinese Clinical Oncology
关键词
恶性黑色素瘤
脑转移
靶向治疗
免疫治疗
Malignant melanoma
Brain metastases
Targeted therapy
Immunotherapy
